Article Text
Abstract
Objective: To determine the effect of torasemide, a loop diuretic with antialdosteronergic properties, compared with furosemide on cardiac sympathetic nerve activity in patients with congestive heart failure (CHF).
Methods: 40 patients with non-ischaemic CHF (left ventricular ejection fraction (LVEF) < 45%) were randomly assigned to torasemide (4–8 mg/day; n = 20) or furosemide (20–40 mg/day; n = 20). All patients were also treated with angiotensin-converting enzyme inhibitor. The delayed heart to mediastinum count (H/M) ratio, delayed total defect score (TDS) and washout rate were determined from iodine-123 meta-iodobenzylguanidine measured before and 6 months after treatment. Left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV) and LVEF were also determined by echocardiography.
Results: After treatment, in patients receiving torasemide, TDS decreased from 44 (8) to 36 (8) (p < 0.001), H/M ratio increased from 1.61 (0.19) to 1.77 (0.24) (p < 0.001), and washout rate decreased from 52 (12)% to 41 (14)% (p = 0.001). In addition, LVEDV decreased from 173 (22) ml to 147 (30) ml (p < 0.001) and LVESV decreased from 117 (19) ml to 95(24) ml (p < 0.001). Although LVEF tended to increase, the change was not significant (from 31 (7)% to 34 (7)%, NS). Conversely, these parameters did not change significantly in patients receiving furosemide. Moreover, percentage change of TDS was significantly correlated with percentage change of LVEDV (r = 0.473, p < 0.05) and of LVESV (r = 0.579, p < 0.01) after torasemide treatment.
Conclusion: These findings indicate that torasemide treatment can ameliorate cardiac sympathetic nerve activity and left ventricular remodelling in patients with CHF.
- ACE, angiotensin-converting enzyme
- BNP, brain natriuretic peptide
- CHF, congestive heart failure
- H/M, heart to mediastinum count ratio
- LVEDV, left ventricular end diastolic volume
- LVEF, left ventricular ejection fraction
- LVESV, left ventricular end systolic volume
- MIBG, meta-iodobenzylguanidine
- NYHA, New York Heart Association
- PIIINP, procollagen type III N-terminal peptide
- RAAS, renin–angiotensin–aldosterone system
- SPECT, single-photon emission computed tomography
- TDS, total defect score
- TORIC, TORasemide In Chronic heart failure
- WR, washout rate
- aldosterone
- heart failure
- loop diuretics
- torasemide
Statistics from Altmetric.com
- ACE, angiotensin-converting enzyme
- BNP, brain natriuretic peptide
- CHF, congestive heart failure
- H/M, heart to mediastinum count ratio
- LVEDV, left ventricular end diastolic volume
- LVEF, left ventricular ejection fraction
- LVESV, left ventricular end systolic volume
- MIBG, meta-iodobenzylguanidine
- NYHA, New York Heart Association
- PIIINP, procollagen type III N-terminal peptide
- RAAS, renin–angiotensin–aldosterone system
- SPECT, single-photon emission computed tomography
- TDS, total defect score
- TORIC, TORasemide In Chronic heart failure
- WR, washout rate
Footnotes
-
Published Online First 18 April 2006
-
Competing interests: None declared.